WAVEMAN · COMPANY

VRDN · Viridian Therapeutics, Inc.\De

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

VRDN

Name: Viridian Therapeutics, Inc.\DE (VRDN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Viridian Therapeutics, Inc.\DE

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001590750

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

$19.7M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+23359.9%

XBRL, annual

NET MARGIN

-483.6%

CONVERSIONS · 180D

codes C/M, not in net · $672.5K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$19.7M over 180 days

-$348.2K over 90 days · +$20.0M of it by a 10%+ holder

more than 96% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

+23359.9% year over year

more than 99% of Pharma & Biotech

MARGIN

-483.6% net margin

below 82% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +19.0%

+19.0%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $19.7M bought by insiders over 180 days, $348.2K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Viridian Therapeutics, Inc.\DE insiders bought a net $19.7M of stock across 43 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Tousignant Jennifer

Chief Legal Officer

SELL

2026-08-19

4,212.0

$103.2K

Tousignant Jennifer

Chief Legal Officer

SELL

2026-08-19

10,000.0

$245.0K

Fairmount Healthcare Fund II L.P.

Director

BUY

2026-05-11

1,176,470.0

$20.0M

Tousignant Jennifer

Chief Legal Officer

SELL

2025-12-31

2,272.0

$70.8K

Fairmount Healthcare Fund II GP LLC

Director

BUY

2025-10-23

454,545.0

$10.0M

43 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 38 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Tousignant Jennifer

FILED 2026-08-19

$348.2K

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$70.8M	$302.0K	$314.0K	$1.8M
OPERATING INCOME	$-363.4M	$-299.0M	$-254.4M	$-134.3M
NET INCOME	$-342.6M	$-269.9M	$-237.7M	$-129.9M
EPS (DILUTED)	—	—	-5.31	-4.05
OPERATING CASH FLOW	$-276.4M	$-232.3M	$-184.2M	$-93.8M
LONG-TERM DEBT	—	$20.6M	$20.2M	$4.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE